The natural history of chlamydia trachomatis infection in women: A multi-parameter evidence synthesis

Health Technology Assessment

Volumn 20, Issue 22, 2016, Pages 1-250

  Price, Malcolm J ^a   Ades, A E ^b   Soldan, Kate ^c   Welton, Nicky J ^b   Macleod, John ^b   Simms, Ian ^c   DeAngelis, Daniela ^c,d   Turner, Katherine M E ^b   Horner, Paddy J ^b,e  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d MRC BIOSTATISTICS UNIT   (United Kingdom)

^e UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ARTICLE; ASYMPTOMATIC INFECTION; CHLAMYDIASIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; ECTOPIC PREGNANCY; ENGLISHMAN; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; FEMALE INFERTILITY; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; LAPAROSCOPY; PELVIC INFLAMMATORY DISEASE; PREVALENCE; REINFECTION; RISK FACTOR; SALPINGITIS; SCREENING TEST; STATISTICAL MODEL; UNITED KINGDOM; ADOLESCENT; ADULT; BAYES THEOREM; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COMPLICATION; FEMALE; MASS SCREENING; PHYSIOLOGY; PREGNANCY; PREGNANCY, ECTOPIC; YOUNG ADULT;

ADOLESCENT; ADULT; BAYES THEOREM; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; PELVIC INFLAMMATORY DISEASE; PREGNANCY; PREGNANCY, ECTOPIC; PREVALENCE; UNITED KINGDOM; YOUNG ADULT;

EID: 84961615920     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta20220     Document Type: Article

References (293)

1. Adams EJ, Turner KME, Edmunds WJ. The cost effectiveness of opportunistic chlamydia screening in England. Sex Transm Infect 2007;83:267-75. http://dx.doi.org/10.1136/sti.2006.024364
2. Roberts TE, Robinson S, Barton PM, Bryan S, McCarthy A, Macleod J, et al. Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK: economic evaluation of chlamydia screening studies (ClaSS) project. BMJ 2007;335:291-8. http://dx.doi.org/10.1136/bmj.39262.683345.AE
3. Public Health England (PHE). National Chlamydia Screening Programme. URL: www.chlamydiascreening.nhs.uk/ps/index.asp. 2014. (6 October 2015).
4. Stephenson J. Screening for genital chlamydial infection. Br Med Bull 1998;5:891-902. http://dx.doi.org/10.1093/oxfordjournals.bmb.a011736
5. Low N. Screening programmes for chlamydial infection: when will we ever learn? BMJ 2007;334:725-8. http://dx.doi.org/10.1136/bmj.39154.378079.BE
6. Wilson J, Junger G. Principles and Practice of Screening for Disease. Geneva: WHO; 1968.
7. Chief Medical Officer’s Expert Advisory Group. Main Report of the CMO’s Expert Advisory Committee on Chlamydia trachomatis. London: Department of Health; 1998.
8. Townshend JRP, Turner HS. Analysing the effectiveness of Chlamydia screening. J Oper Res Soc 2000;51:812-24. http://dx.doi.org/10.1057/palgrave.jors.2600978
9. Department of Health (DH). The National Strategy for Sexual Health and HIV. London: DH; 2001.
10. Public Health England (PHE). The UK National Screening Committee Policy on Chlamydia Screening in Adults. 2006. URL: http://legacy.screening.nhs.uk/chlamydia-adult (accessed 6 October 2015).
11. Sheringham J, Baraitser P, Simms I. Chlamydia screening in England: a qualitative study of the narrative behind the policy. BMC Publ Health 2012;12.
12. Ostergaard L, Andersen B, Moller JK, Olesen F. Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. Clin Infect Dis 2000;31:951-7. http://dx.doi.org/10.1086/318139
13. Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996;334:1362-6. http://dx.doi.org/10.1056/NEJM199605233342103
14. Abter EIM. Screening for Chlamydia to prevent pelvic inflammatory disease. N Engl J Med 1996;335:1531-3. http://dx.doi.org/10.1056/NEJM199611143352012
15. Low N, McCarthy A, Macleod J, Salisbury C, Campbell R, Roberts TE, et al. Epidemiological, social, diagnostic, and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess 2007;11(8). http://dx.doi.org/10.3310/hta11080
16. European Centre for Disease Control and Prevention (ECDC). Review of Chlamydia Control Activities in EU Countries: Technical Report. Stockholm: ECDC; 2008.
17. Nelson H, Helfand M. Screening for chlamydial infection. Am J Prev Med 2001;20:95-107. http://dx.doi.org/10.1016/S0749-3797(01)00253-7
18. Low N, Bender N, Nartey L, Shang A, Stephenson JM. Effectiveness of chlamydia screening: systematic review. Int J Epidemiol 2009;38:435-48. http://dx.doi.org/10.1093/ije/dyn222
19. Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ 2010;340:c1642. http://dx.doi.org/10.1136/bmj.c1642
20. Gottlieb S, Berman S, Low N. Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection: how much do we know? J Infect Dis 2010;201:156-67. http://dx.doi.org/10.1086/652396
21. Sheringham J. Screening for chlamydia. BMJ 2010;340:c1698. http://dx.doi.org/10.1136/bmj.c1698
22. Van den Broek IVF, van Bergen JEAM, Brouwers EEHG, et al. Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. BMJ 2012;344. http://dx.doi.org/10.1136/bmj.e4316
23. Anderson B, van Valkengoed I, Skolowski I, Moller J, Ostergaard L, Olesen F. Impact of intensified testing for urogenital Chlamydia trachomatis infections: a randomised study with 9-year follow-up. Sex Transm Infect 2010;87:156-61. http://dx.doi.org/10.1136/sti.2010.042192
24. Soldan K, Berman S. Danish health register study: a randomised trial with findings about the implementation of chlamydia screening, but not about its benefits. Sex Transm Infect 2011;87:86-7. http://dx.doi.org/10.1136/sti.2010.048082
25. Hocking J. Protocol 12PRT/9010:Australian Chlamydia Control Effectiveness Pilot (ACCEPt): a cluster randomised controlled trial of chlamydia testing in general practice (ACTRN1260000297022). URL: www.thelancet.com/protocol-reviews/12PRT-9010. 2010 (accessed 6 October 2015).
26. Kretzschmar M, Turner KME, Barton PM, Edmunds WJ, Low N. Predicting the population impact of chlamydia screening programmes: comparative mathematical modelling study. Sex Transm Infect 2009;85:359-66. http://dx.doi.org/10.1136/sti.2009.036251
27. Althaus CL, Turner KME, Schmid BV, Heijne JCM, Kretzschmar M, Low N. Transmission of Chlamydia trachomatis through sexual partnerships: a comparison between three individual-based models and empirical data. J R Soc Interface 2012;9:136-46. http://dx.doi.org/10.1098/rsif.2011.0131
28. Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005;5:149-61. http://dx.doi.org/10.1038/nri1551
29. Hu D, Hook EW, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. Ann Int Med 2004;141:501-13. http://dx.doi.org/10.7326/0003-4819-141-7-200410050-00006
30. Hu D, Hook EW, Goldie SJ. The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies. Sex Transm Dis 2006;33:428-36. http://dx.doi.org/10.1097/01.olq.0000200577.46261.b0
31. Paavonen J, Eggert-Kruse W. Chlamydia trachomatis: impact on human reproduction. Hum Reprod Update 1999;5:433-47. http://dx.doi.org/10.1093/humupd/5.5.433
32. Welte R, Postma M, Leidl R, Kretzschmar M. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis 2005;32:474-83. http://dx.doi.org/10.1097/01.olq.0000161181.48687.cf
33. Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992;19:185-92. http://dx.doi.org/10.1097/00007435-199207000-00001
34. Westrom LV. Sexually-transmitted diseases and infertility. Sex Transm Dis 1994;21:S32-7.
35. Cahill DJ, Wardle PG. Management of infertility. BMJ 2002;325:28-32. http://dx.doi.org/10.1136/bmj.325.7354.28
36. Low N, Egger M, Sterne JAC, Harbord RM, Ibrahim F, Lindblom B, et al. Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women’s Cohort Study. Sex Transm Infect 2006;82:212-18. http://dx.doi.org/10.1136/sti.2005.017186
37. Simms I, Stephenson JM, Mallinson H, Peeling RW, Thomas K, Gokhale R, et al. Risk factors associated with pelvic inflammatory disease. Sex Transm Infect 2006;82:452-7. http://dx.doi.org/10.1136/sti.2005.019539
38. Gottlieb SL, Martin DH, Xu FJ, Byrne GI, Brunham RC. Summary: the natural history and immunobiology of Chlamydia trachomatis genital infection and implications for Chlamydia control. J Infect Dis 2010;201:S190-204. http://dx.doi.org/10.1086/652401
39. Van Valkengoed IGM, Morre SA, van den Brule AJC, Meijer CJLM, Bouter LM, Boeke AJP. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes - implications for cost-effectiveness analyses. Int J Epidemiol 2004;33:416-25. http://dx.doi.org/10.1093/ije/dyh029
40. Simms I, Horner P. Has the incidence of pelvic inflammatory disease following chlamydial infection been overestimated? Int J STD AIDS 2008;19:285-6. http://dx.doi.org/10.1258/ijsa.2007.007316
41. Guyatt G, Sackett D, Sinclair J, Hayward R, Cook D, Cook R. Users’ guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA 1885;274:1800-04. http://dx.doi.org/10.1001/jama.1995.03530220066035
42. Ades AE, Sutton AJ. Multiparameter evidence synthesis in epidemiology and medical decision making: current approaches. Stat Soc 2006;169:5-35. http://dx.doi.org/10.1111/j.1467-985X.2005.00377.x
43. Ades AE, Welton N, Caldwell D, Price M, Goubar A, Lu G. Multiparameter evidence synthesis in epidemiology and medical decision-making. J Health Serv Res Policy 2008;13:12-22. http://dx.doi.org/10.1258/jhsrp.2008.008020
44. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS User Manual Version 1.4, January 2003. Upgraded to Version 1.4.3, 2007. (www.mrc-bsu.cam.ac.uk/bugs)
45. Birge R. Probable values of e, h, e/m, and a. Phys Rev 1932;40:228-61. http://dx.doi.org/10.1103/PhysRev.40.228
46. Brand KP, Small MJ. Updating uncertainty in an integrated risk assessment: conceptual framework and methods. Risk Anal 1995;15:719-31. http://dx.doi.org/10.1111/j.1539-6924.1995.tb01344.x
47. Poole D, Raftery AE. Inference for deterministic simulation models: the Bayesian melding approach. J Am Stat Assoc 2000;95:1244-55. http://dx.doi.org/10.1080/01621459.2000.10474324
48. Raftery AE, Givens GH, Zeh JE. Inference from a deterministic population dynamics model for Bowhead whales (with discussion). J Am Stat Assoc 1995;90:402-30. http://dx.doi.org/10.1080/01621459.1995.10476529
49. Hasselblad V, McCrory DC. Meta-analytic tools for medical decision making: a practical guide. Med Decis Making 1995;15:81-96. http://dx.doi.org/10.1177/0272989X9501500112
50. Eddy DM, Hasselblad V, Shachter R. Meta-analysis by the Confidence Profile Method. London: Academic Press; 1992.
51. Sutton AJ, Abrams KR, Ades AE, Cooper NJ, Welton NJ. Evidence Synthesis for Decision Making. Chichester: Wiley; 2008.
52. Goubar A, Ades AE, De Angelis D, Tom BD, Birrell PJ, Charlett A, et al. Estimates of human immunodeficiency virus prevalence and proportion diagnosed based on Bayesian multiparameter synthesis of surveillance data. J Roy Stat Soc A 2008;171:541-80. http://dx.doi.org/10.1111/j.1467-985X.2007.00537.x
53. Presanis A, Pebody RG, Paterson BJ, Tom BD, Birrell PJ, Charlett A, et al. Changes in the severity of the 2009 pandemic A/H1N1 influenza in England: a Bayesian evidence synthesis. BMJ 2011;343:d5408. http://dx.doi.org/10.1136/bmj.d5408
54. Presanis AM, Gill ON, Chadborn TR, Hill C, Hope V, Logan L, et al. Insights into the rise in HIV infections in England and Wales, 2001 to 2008: a Bayesian synthesis of prevalence studies. Aids 2010;24:2849-58. http://dx.doi.org/10.1097/QAD.0b013e32834021ed
55. Sweeting MJ, De Angelis D, Hickman D, Ades AE. Estimating HCV prevalence in England and Wales by synthesising evidence from multiple data sources: assessing data conflict and model fit. Biostatistics 2008;9:715-34. http://dx.doi.org/10.1093/biostatistics/kxn004
56. Colbourn TE, Asseburg C, Bojke L, Phillips Z, Welton NJ, Claxton A, et al. Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses. BMJ 2007;335:655-61. http://dx.doi.org/10.1136/bmj.39325.681806.AD
57. Ades AE, Cliffe S. Markov Chain Monte Carlo estimation of a multi-parameter decision model: consistency of evidence and the accurate assessment of uncertainty. Medical Decision Making 2002;22:359-71. http://dx.doi.org/10.1177/027298902400448920
58. Cooper H, Hedges L. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994.
59. Sutton AJ, Higgins JPT. Recent developments in meta-analysis. Stat Med 2008;27:625-50. http://dx.doi.org/10.1002/sim.2934
60. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Chichester: The Cochrane Collaboration, Wiley; 2008.
61. Land JA, van Bergen JEAM, Morre SA, Postma MJ. Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update 2010;16:189-204. http://dx.doi.org/10.1093/humupd/dmp035
62. Simms I, Stephenson JM. Pelvic inflammatory disease epidemiology: what do we know and what do we need to know? Sex Transm Infect 2000;76:80-7. http://dx.doi.org/10.1136/sti.76.2.80
63. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010;59:1-116.
64. Horner P, Boag F. UK National Guideline for the Management of Genital Tract Infection with Chlamydia trachomatis. 2006. URL: http://www.bashh.org/documents/65.pdf (accessed 6 October 2015).
65. Black CM. Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin Microbiol Rev 1997;10:160-84.
66. Cameron ST, Glasier A, Scott G, Young H, Melvin L, Johnstone A, et al. Novel interventions to reduce re-infection in women with chlamydia: a randomized controlled trial. Hum Reprod 2009;24:888-95. http://dx.doi.org/10.1093/humrep/den475
67. Cameron ST, Glasier A, Muir A, Scott G, Johnstone A, Quarrell H, et al. Expedited partner therapy for Chlamydia trachomatis at the community pharmacy. BJOG 2010;117:1074-9. http://dx.doi.org/10.1111/j.1471-0528.2010.02573.x
68. Dombrowski JC, Golden MR. Accelerated partner therapy: a promising new partner treatment option. Sex Transm Infect 2012;88:2-3. http://dx.doi.org/10.1136/sextrans-2011-050377
69. Estcourt C, Sutcliffe L, Cassell J, Mercer CH, Copas A, James L, et al. Can we improve partner notification rates through expedited partner therapy in the UK? Findings from an exploratory trial of Accelerated Partner Therapy (APT). Sex Transm Infect 2012;88:21-6. http://dx.doi.org/10.1136/sti.2010.047258
70. Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, Hogben M, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005;352:676-85. http://dx.doi.org/10.1056/NEJMoa041681
71. Shiely FPHD, Hayes KPHD, Thomas KM, Kerani RP, Hughes JP, Whittington WL, et al. Expedited partner therapy: a robust intervention. Sex Transm Dis 2010;37:602-7. http://dx.doi.org/10.1097/olq.0b013e3181e1a296
72. Van den Broek IV, Hoebe CJ, van Bergen JE, Brouwers EE, de Feijter EM, Fennema JS, et al. Evaluation design of a systematic, selective, internet-based, Chlamydia screening implementation in the Netherlands, 2008-2010: implications of first results for the analysis. BMC Infect Dis 2010;10:89. http://dx.doi.org/10.1186/1471-2334-10-89
73. Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook EW. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis 2008;35:119-23. http://dx.doi.org/10.1097/OLQ.0b013e318151497d
74. Geisler WM. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. J Infect Dis 2010;201:S104-13. http://dx.doi.org/10.1086/652402
75. Cates W, Steiner M. Dual protection against unintended pregnancy and sexually transmitted infections: what is the best contraceptive approach? Sex Transm Dis 2002;293:168-74. http://dx.doi.org/10.1097/00007435-200203000-00007
76. Althaus C, Heijne J, Low N. Towards more robust estimates of the transmissibility of Chlamydia trachomatis. Sex Transm Dis 2012;39:402-4. http://dx.doi.org/10.1097/OLQ.0b013e318248a550
77. Faculty of Sexual and Reproductive Healthcare. Emergency Contraception. London: Royal College of Obstetricians and Gynaecologists; 2012.
78. Faculty of Forensic and Legal Medicine. Recommendations for the Collection of Forensic Specimens from Complainants and Suspects. London: Royal College of Physicians; 2014.
79. Joyner JL, Douglas JM, Foster M, Judson FN. Persistence of Chlamydia trachomatis infection detected by polymerase chain reaction in untreated patients. Sex Transm Dis 2002;29:196-200. http://dx.doi.org/10.1097/00007435-200204000-00002
80. Geisler W, Lensing S, Press C. Spontaneous resolution of genital Chlamydia trachomatis Infection in women and protection from reinfection. J Infect Dis 2013;207:1850-56. http://dx.doi.org/10.1093/infdis/jit094
81. Macleod J, Salisbury C, Low N, McCarthy A, Sterne JA, Holloway A, et al. Coverage and uptake of systematic postal screening for genital Chlamydia trachomatis and prevalence of infection in the United Kingdom general population: cross sectional study. BMJ 2005;330:940-2. http://dx.doi.org/10.1136/bmj.38413.663137.8F
82. Paavonen J, Westrom L, Eschenbach DA. Pelvic Inflammatory Disease. In Holmes K, Sparling PF, Stamm WE, editors. Sexually Transmitted Disease. 4th edn. London: McGraw Hill; 2008:1021-2.
83. British Association for Sexual Health and HIV (BASHH) Clinical Effectiveness Group. UK National Guideline for the Management of Pelvic Inflammatory Disease 2011. Macclesfield: BASHH; 2011.
84. Hillis SD, Joesoef R, Marchbanks PA, Wasserheit JN, Cates W, Westrom L. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993;168:1503-9. http://dx.doi.org/10.1016/S0002-9378(11)90790-X
85. Treharne JD, Ripa KT, Mardh PA, Svensson L, Westrom L, Darougar S. Antibodies to Chlamydia trachomatis in acute salpingitis. Brit J Vener Dis 1979;55:26-9. http://dx.doi.org/10.1136/sti.55.1.26
86. Ness R, Keder L, Soper D. Oral contraception and the recognition of endometritis. Am J Obstet Gynecol 1997;176:580-5. http://dx.doi.org/10.1016/S0002-9378(97)70551-9
87. Ness RB, Soper DE, Peipert J, Sondheimer SJ, Holley RL, Sweet RL, et al. Design of the PID Evaluation and Clinical Health (PEACH) Study. Control Clin Trials 1998;19:499-514. http://dx.doi.org/10.1016/S0197-2456(98)00022-1
88. Taylor-Robinson D, Stacey CM, Jensen JS, Thomas BJ, Munday PE. Further observations, mainly serological, on a cohort of women with or without pelvic inflammatory disease. Int J STD AIDS 2009;20:712-18. http://dx.doi.org/10.1258/ijsa.2008.008489
89. Hager W, Eschenbach D, Spence M. Criteria for diagnosis and grading of salpingitis. Obstet Gynecol 1983;61:113-14.
90. French CE, Hughes G, Nicholson A, Jung M, Ross JD, Williams T, et al. Estimation of the rate of pelvic inflammatory disease diagnoses: trends in England, 2000-2008. Sex Transm Dis 2011;38:158-62. http://dx.doi.org/10.1097/OLQ.0b013e3181f22f3e
91. Horner P, Blee K, Adams E. Time to manage Mycoplasma genitalium as an STI: but not with azithromycin 1 gram! Current Opinion in Infectious Diseases 2014;27:68-74. http://dx.doi.org/10.1097/QCO.0000000000000030
92. Brotman R, Ravel J, Bavoil P. Microbiome, sex hormones, and immune responses in the reproductive tract: challenges for vaccine development against sexually transmitted infections. Vaccine 2014;32:1543-52. http://dx.doi.org/10.1016/j.vaccine.2013.10.010
93. Mehta S. Systematic review of randomized trials of treatment of male sexual partners for improved bacterial vaginosis outcomes in women. Sex Transm Dis 2012;39:822-30. http://dx.doi.org/10.1097/OLQ.0b013e3182631d89
94. Koumans EH, Sternberg M, Bruce C, McQuillan G, Kenddrick J, Sutton M, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007;34:864-9. http://dx.doi.org/10.1097/OLQ.0b013e318074e565
95. British Association for Sexual Health and HIV (BASHH) Clinical Effectiveness Group. UK National Guideline for the Management of Bacterial Vaginosis. Macclesfield: BASHH; 2012.
96. Martin DH. The microbiota of the vagina and its influence on women’s health and disease. Am J Med Sci 2012;343:2-9. http://dx.doi.org/10.1097/MAJ.0b013e31823ea228
97. Nicholson A, Rait G, Murray-Thomas T, Hughes G, Mercer C, Cassell J. Management of first episode pelvic inflammatory disease in primary care: results form a large primary care database. Br J Gen Pract 2010;60. http://dx.doi.org/10.3399/bjgp10x532404
98. Haggerty C, Gottlieb S, Taylor B, Low N, Xu F, Ness R. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 2010;201:S134-55. http://dx.doi.org/10.1086/652395
99. Sellors JW, Mahony JB, Chernesky MA, Rath DJ. Tubal factor infertility: an association with prior chlamydial Infection and asymptomatic salpingitis. Fertil Steril 1988;49:451-7.
100. Cates W, Joesoef MR, Goldman MB. Atypical pelvic inflammatory disease: can we identify clinical predictors. Am J Obstet Gynecol 1993;169:341-6. http://dx.doi.org/10.1016/0002-9378(93) 90085-W
101. Svensson L, Westrom L, Ripa KT, Mardh PA. Differences in some clinical and laboratory parameters in acute salpingitis related to culture and serologic findings. Am J Obstet Gynecol 1980;138:1017-21.
102. Osser S, Persson K, Liedholm P. Tubal infertility and silent chlamydial salpingitis. Hum Reprod 1989;4:280-4.
103. Wolner-Hanssen P. Silent pelvic inflammatory disease: is it overstated? Obstet Gynecol 1995;86:321-5. http://dx.doi.org/10.1016/0029-7844(95)00177-S
104. National Institute for Health and Care Excellence (NICE). Pelvic Inflammatory Disease. Clinical Knowledge Summary. 2013. URL: http://cks.nice.org.uk/pelvic-inflammatory-disease#!topicsummary (accessed 6 October 2015).
105. Lazaro N. Sexually Transmitted Infections in Primary Care 2013. RCGP/BASHH. 2nd edn. London: Royal College of General Practitioners; 2013. (www.rcgp.org and www.bashh.org/guidelines)
106. Adams EJ, Charlett A, Edmunds WJ, Hughes G. Chlamydia trachomatis in the United Kingdom: a systematic review and analysis of prevalence studies. Sex Transm Infect 2004;80:354-62. http://dx.doi.org/10.1136/sti.2003.005454
107. Hillis SD, Owens LM, Marchbanks PA, Amsterdam LF, MacKenzie WR. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997;176:103-7. http://dx.doi.org/10.1016/S0002-9378(97)80020-8
108. Eschenbach DA, Buchanan TM, Pollock HM, Forsyth PS, Alexander ER, Linn JS, et al. Polymicrobial etiology of acute pelvic inflammatory disease. N Engl J Med 1975;293:166-71. http://dx.doi.org/10.1056/NEJM197507242930403
109. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 2007;109:114-20. http://dx.doi.org/10.1097/01.AOG.0000247627.84791.91
110. Westrom L, Bengtsson LP, Mardh PA. Incidence, trends, and risks of ectopic pregnancy in a population of women. Br Med J 1981;282:15-18. http://dx.doi.org/10.1136/bmj.282.6257.15
111. Peipert J, Ness R, Blume J. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. Am J Obstet Gynecol 2001;184:856-63. http://dx.doi.org/10.1067/mob.2001.113847
112. Sellors J, Mahony J, Goldsmith C, Rath D, Mander R, Hunter B, et al. The accuracy of clinical findings and laparoscopy in pelvic inflammatory disease. Am J Obstet Gynecol 1991;164:113-20. http://dx.doi.org/10.1016/0002-9378(91)90639-9
113. Westrom L, Wolner-Hanssen P. Pathogenesis of pelvic inflammatory disease. Genitourin Med 1993;69:9-17. http://dx.doi.org/10.1136/sti.69.1.9
114. Short VL, Totten PA, Ness RB, Astete SG, Kelsey SF, Haggerty CL. Clinical presentation of Mycoplasma genitalium infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis 2009;48:41-7. http://dx.doi.org/10.1086/594123
115. Taylor B, Ness R, Darville T. Microbial correlates of delayed care for pelvic inflammatory disease. Sex Transm Dis 2011;387:434-8. http://dx.doi.org/10.1097/OLQ.0b013e3181ffa7c7
116. Farquhar CM. Ectopic pregnancy. Lancet 2005;366:583-91. http://dx.doi.org/10.1016/S0140-6736(05)67103-6
117. Health & Social Care Information Centre (HSCIC). Hospital Episode Statistics 2012. URL: www.hscic.gov.uk/hes (accessed 11 December 2012).
118. Office for National Statistics (ONS). Conception Statistics, England and Wales. 2012. URL: www.ons.gov.uk/ons/publications/all-releases.html?definition=tcm%3A77-27423 (accessed 10 October 2012).
119. Coste J, Jobspira N, Aubletcuvelier B, Germain E, Glowackzower E, Fernandez H, et al. Incidence of ectopic pregnancy: first results of a population-based register in France. Hum Reprod 1994;9:742-5.
120. Hoover KW, Tao G, Kent CK. Trends in the diagnosis and treatment of ectopic pregnancy in the United States. Obstet Gynecol 2010;115:495-502. http://dx.doi.org/10.1097/AOG.0b013e3181d0c328
121. Egger M, Low N, Smith GD, Lindblom B, Herrmann B. Screening for chlamydial infections and the risk of ectopic pregnancy in a county in Sweden: ecological analysis. BMJ 1998;316(7147):1776-80. http://dx.doi.org/10.1136/bmj.316.7147.1776
122. Trabert B, Holt VL, Yu O, Van den Eeden SK, Scholes D. Population-based ectopic pregnancy trends, 1993-2007. Am J Prev MEd 2011;40:556-60. http://dx.doi.org/10.1016/j.amepre.2010.12.026
123. Simms I, Rogers PA, Nicoll A. The influence of demographic change and cumulative risk of pelvic inflammatory disease on the incidence of ectopic pregnancy. Epidemiol Infect 1997;119:49-52. http://dx.doi.org/10.1017/S0950268897007711
124. Westrom L. Effect of pelvic inflammatory disease on fertility. Venereology 1995;8:219-22.
125. National Collaborating Centre for Women’s and Children’s Health. Fertility: Assessment and Treatment for People with Fertility Problems. London: Royal College of Obstetricians and Gynaecologists; 2013.
126. Templeton A, Fraser C, Thompson B. The Epidemiology of infertility in Aberdeen. BMJ 1990;301:148-52. http://dx.doi.org/10.1136/bmj.301.6744.148
127. Bhattacharya S, Porter M, Amalraj E, Templeton A, Hamilton M, Lee AJ, et al. The epidemiology of infertility in the North East of Scotland. Hum Reprod 2009;24:3096-107. http://dx.doi.org/10.1093/humrep/dep287
128. Gunnell DJ, Ewings P. Infertility prevalence, needs assessment and purchasing. J Publ Health Med 1994;16:29-35.
129. Oakley L, Doyle P, Maconochie N. Lifetime prevalence of infertility and infertility treatment in the UK: results from a population-based survey of reproduction. Hum Reprod 2008;23:447-50. http://dx.doi.org/10.1093/humrep/dem369
130. Human Fertilisation and Embryology Authority (HFEA). Facts and Figures. Long-term Trends Data - Patients Treated. 2011. URL: www.hfea.gov.uk/2585.html (accessed 7 October 2015).
131. Human Fertilisation and Embryology Authority. Facts and Figures 2006: Fertility Problems and Treatment. London: HFEA; 2008.
132. Howard FM. Chronic Pelvic Pain. Obstet Gynecol 2003;101:594-611. http://dx.doi.org/10.1016/S0029-7844(02)02723-0
133. Thorne C. UK National Screening Committee Policy Review: Chlamydia Screening in Pregnancy: an Evidence Review. London: National Screening Committee; 2011. (www.screening.nhs.uk/chlamydia-pregnancy)
134. Kaltenthaler E, Tappenden P, Paisley S, Squires H. Identifying and Reviewing Evidence to Inform the Conceptualisation and Population of Cost-effectiveness Models. NICE Decision Support Unit, Technical Support Document 13. Sheffield: University of Sheffield; 2011.
135. Pirolli P, Card S. Information foraging. Psychol Rev 1999;106:643-75. http://dx.doi.org/10.1037/0033-295X.106.4.643
136. Glanville J, Paisley S. Searching for Evidence for Cost-Effectiveness Decisions. In Shemilt I, Mugford M, Vale L, Marsh K, Donaldson C, editors. Evidence-based Decisions and Economics: Health Care, Social Welfare, Education and Criminal Justice. Oxford: Wiley-Blackwell; 2010. http://dx.doi.org/10.1002/9781444320398.ch7
137. Kretzschmar M, Welte R, Van den Hoek A, Postma MJ. Comparative model-based analysis of screening programs for Chlamydia trachomatis infections. Am J Epidemiol 2001;153:90-101. http://dx.doi.org/10.1093/aje/153.1.90
138. Kretzschmar M, van Duynhoven YT, Severijnen AJ. Modeling prevention strategies for gonorrhea and Chlamydia using stochastic network simulations. Am J Epidemiol 1996;144:306-17. http://dx.doi.org/10.1093/oxfordjournals.aje.a008926
139. Golden MR, Schillinger JA, Markowitz L, St Louis ME. Duration of untreated genital infections with Chlamydia trachomatis: a review of the literature. Sex Transm Dis 2000;27:329-37. http://dx.doi.org/10.1097/00007435-200007000-00006
140. Turner KME, Adams EJ, Gay N, Ghani AC, Mercer C, Edmunds WJ. Developing a realistic sexual network model of chlamydia transmission in Britain. Theor Biol Med Model 2006;3:3. http://dx.doi.org/10.1186/1742-4682-3-3
141. Turner KME, Adams EJ, LaMontagne DS, Emmett L, Baster K, Edmunds WJ. Modelling the effectiveness of chlamydia screening in England. Sex Transm Infect 2006;82:496-502. http://dx.doi.org/10.1136/sti.2005.019067
142. Korenromp EL, Sudaryo MK, de Vlas SJ, Gray RH, Sewankambo NK, Serwadda D, et al. What proportion of episodes of gonorrhoea and chlamydia becomes symptomatic? Int J STD AIDS 2002;13:91-101. http://dx.doi.org/10.1258/0956462021924712
143. Mol BWJ, Dijkman B, Wertheim P, Lijmer J, VanderVeen F, Bossuyt PMM. The accuracy of serum chlamydial antibodies in the diagnosis of tubal pathology: a meta-analysis. Fertil Steril 1997;67:1031-7. http://dx.doi.org/10.1016/S0015-0282(97)81435-5
144. Risser WL, Risser JMH. The incidence of pelvic inflammatory disease in untreated women infected with Chlamydia trachomatis: a structured review. Int J STD AIDS 2007;18:727-31. http://dx.doi.org/10.1258/095646207782212351
145. Wallace LA, Scouler A, Hart G. What is the excess risk of infertility in women after genital chlamydia infection? A systematic review of the evidence. Sex Transm Infect 2008;84:171-5. http://dx.doi.org/10.1136/sti.2007.026047
146. Watson EJ, Templeton A, Russell I, Paavonen J, Mardh PA, Stary A, et al. The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review. J Med Microbiol 2002;51:1021-31. http://dx.doi.org/10.1099/0022-1317-51-12-1021
147. Ankum WM, Mol BWJ, VanderVeen F, Bossuyt PMM. Risk factors for ectopic pregnancy: a meta-analysis. Fertil Steril 1996;65:1093-9.
148. Rockhill B, Newmam B, Weinberg C. Use and misuse of population attributable fractions. Am J Publ Health 1998;88:15-19. http://dx.doi.org/10.2105/AJPH.88.1.15
149. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd edn. Philadelphia: Lippincott, Williams & Wilkins; 2008.
150. Spiegelhalter DJ, Abrams KR, Myles J. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York: Wiley; 2004.
151. Hastings WK. Monte Carlo sampling methods using Markov Chains and their applications. Biometrika 1970;57:97-109. http://dx.doi.org/10.1093/biomet/57.1.97
152. Gilks WR, Richardson S, Spiegelhalter DJ. Markov Chain Monte Carlo in Practice. London: Chapman & Hall/CRC; 1996.
153. Gelman A, Carlin JG, Stern HS, Rubin DB. Bayesian Data Analysis. 1st edn. London: Chapman & Hall; 1995.
154. Geman S, Geman D. Stochastic relaxation, Gibbs distributions, and the Bayesian restoration of images. IEEE Transactions on Pattern Analysis and Machine Intelligence 1984;6:721-41. http://dx.doi.org/10.1109/TPAMI.1984.4767596
155. Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998;7:434-55.
156. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. J Roy Stat Soc B 2002;64:583-616. http://dx.doi.org/10.1111/1467-9868.00353
157. Dempster AP. The direct use of likelihood for significance testing. Stat Comput 1997;7:247-52. http://dx.doi.org/10.1023/A:1018598421607
158. Akaike H. Likelihood of a model and information criteria. J Econometrics 1981;16:3-14. http://dx.doi.org/10.1016/0304-4076(81)90071-3
159. Spiegelhalter DJ, Best N, Carlin BP. Bayesian Deviance: the Effective Number of Parameters, and the Comparison of Arbitrarily Complex Models. Technical Report 98-009. Division of Biostatistics. Minneapolis, MN: University of Minnesota; 1998.
160. Lunn D. WinBUGS Development Interface (WBDev). 2004. URL: http://winbugs-development.mrc-bsu.cam.ac.uk/(accessed 21 March 2013).
161. Lunn D. WinBUGS Differential Interface (WBDiff). 2004. URL: http://winbugs-development.mrc-bsu.cam.ac.uk/(accessed 21 March 2013).
162. O’Hagan A. HSSS Model Criticism. In Green PJ, editor. Highly Structured Stochastic Systems. Oxford: Oxford University Press; 2002.
163. Ohlssen D, Spiegelhalter DJ. Conflict Diagnosis in Directed Acyclic Graphs. MRC Public Health Service Research Network Workshop, 2006.
164. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking Consistency in Mixed Treatment Comparison Meta-analysis. Stat Med 2010;29:932-44. http://dx.doi.org/10.1002/sim.3767
165. Rahm VA, Belsheim J, Gleerup A, Gnarpe H, Rosen G. Asymptomatic carriage of Chlamydia trachomatis: a study of 109 teenage girls. Eur J Sex Transm Dis 1986;3:91-4.
166. Althaus C, Heijne J, Roellin A, Low N. Transmission dynamics of Chlamydia trachomatis affect the impact of screening programs. Epidemics 2010;2:123-31. http://dx.doi.org/10.1016/j.epidem.2010.04.002
167. Jewell NP. Mixtures of exponential distributions. Ann Stat 1982;10:479-84. http://dx.doi.org/10.1214/aos/1176345789
168. Price MJ, Ades AE, Angelis DD, Welton NJ, Mcleod J, Soldan K, et al. Mixture-of-exponentials models to explain heterogeneity in studies of the duration of Chlamydia trachomatis infection. Stat Med 2013;32:1547-60. http://dx.doi.org/10.1002/sim.5603
169. Molano M, Meijer CJLM, Weiderpass E, Arslan A, Posso H, Franceschi S, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis 2005;191:907-16. http://dx.doi.org/10.1086/428287
170. Ginocchio RHS, Veenstra DL, Connell FA, Marrazzo JM. The clinical and economic consequences of screening young men for genital chlamydial infection. Sex Transm Dis 2003;30:99-106. http://dx.doi.org/10.1097/00007435-200302000-00001
171. Goeree R, Jang D, Blackhouse G, Chong S, Mahoney J, Sellors J, et al. Cost-effectiveness of screening swab or urine specimens for Chlamydia trachomatis from young Canadian women in Ontario. Sex Transm Dis 2001;28:701-9. http://dx.doi.org/10.1097/00007435-200112000-00007
172. Mehta SD, Bishai D, Howell R, Rothman RE, Quinn TC, Zenilman JM. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. Sex Transm Dis 2002;29:83-91. http://dx.doi.org/10.1097/00007435-200202000-00004
173. Wang LY, Burstein GR, Cohen DA. An economic evaluation of a school-based sexually transmitted disease screening program. Sex Transm Dis 2002;29:737-45. http://dx.doi.org/10.1097/00007435-200212000-00001
174. Welte R, Kretzschmar M, Leidl R, Van den Hoek A, Jager JC, Postma MJ. Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach. Sex Transm Dis 2000;27:518-29. http://dx.doi.org/10.1097/00007435-200010000-00005
175. Rogers SM, Miller WC, Turner CF, Elen J, Zenilman J, Rothman R, et al. Concordance of Chlamydia trachomatis infections within sexual partnerships. Sex Transm Infect 2008;84:23-8. http://dx.doi.org/10.1136/sti.2007.027029
176. Parks KS, Dixon PB, Richey CM, Hook EW. Spontaneous clearance of Chlamydia trachomatis infection in untreated patients. Sex Transm Dis 1997;24:229-35. http://dx.doi.org/10.1097/00007435-199704000-00008
177. Schachter J, Hanna L, Hill EC, Massad S, Sheppard CW, Conte JE, Jr, et al. Are chlamydial infections the most prevalent venereal disease. JAMA 1975;231:1252-5. http://dx.doi.org/10.1001/jama.1975.03240240022018
178. Tsukagoshi T. Epidemiological study on Chlamydia trachomatis infection among sexually active female adolescents. Acta Obstet Gynaecol Jpn 1990;42:1655-62.
179. Van Valkengoed IGM, Morre SA, van den Brule AJC, Meijer CJ, Bouter LM, van Eijk JT, et al. Follow-up, treatment, and reinfection rates among asymptomatic Chlamydia trachomatis cases in general practice. Br J Gen Pract 2002;52:623-7.
180. Morre SA, van den Brule AJC, Rozendaal L, Boeke AJ, Voorhorst FJ, deBlok S, et al. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS 2002;13:12-18. http://dx.doi.org/10.1258/095646202762226092
181. Sheffield JS, Andrews WW, Klebanoff MA, Macpherson C, Carey JC, Ernest JM, et al. Spontaneous resolution of asymptomatic Chlamydia trachomatis in pregnancy. Obstet Gynecol 2005;105:557-62. http://dx.doi.org/10.1097/01.AOG.0000153533.13658.c2
182. Alexander ER, Chandler J, Pheifer TA, Wang S-P, English M, Holmes KK. Prospective Study of Perinatal Chlamydia-Trachomatis Infection. In Hobson D, King Holmes, editors. Nongonococcal Urethritis and Related Infections. Washington DC; American Society for Microbiology; 1977.
183. Johannisson G, Lowhagen GB, Lycke E. Genital Chlamydia trachomatis infection in women. Obstet Gynecol 1980;56:671-5.
184. Paavonen J, Kousa M, Saikku P, Vartiainen E, Kanerva L, Lassus A. Treatment of non-Gonococcal urethritis with trimethoprim-sulfadiazine and with placebo: a double-blind partner-controlled study. Brit J Vener Dis 1980;56:101-4.
185. Sorensen JL, Thranov I, Hoff G, Dirach J. Early-onset and late-onset pelvic inflammatory disease among women with cervical Chlamydia trachomatis infection at the time of induced abortion: a follow-up study. Infection 1994;22:242-6. http://dx.doi.org/10.1007/BF01739907
186. McCormack WM, Alpert S, Mccomb DE, Nichols RL, Semine DZ, Zinner SH. 15-Month follow-up study of women infected with Chlamydia trachomatis. N Engl J Med 1979;300:123-5. http://dx.doi.org/10.1056/NEJM197901183000305
187. McCullagh P, Nelder JA. Generalised Linear Models. 2nd edn. London: Chapman & Hall; 1989. http://dx.doi.org/10.1007/978-1-4899-3242-6
188. Zelen M, Feinleib M. On the theory of screening for chronic diseases. Biometrika 1969;56:601-14. http://dx.doi.org/10.1093/biomet/56.3.601
189. Jamieson DJ, Theiler RN, Rasmussen SA. Emerging infections and pregnancy. Emerg Infect Dis 2006;12:1638-43. http://dx.doi.org/10.3201/eid1211.060152
190. Mallinson H, Hopwood J, Mutton K. Resolution of the recent performance problem of Abbott LCx Chlamydia trachomatis assay. Issues of repeat testing for confirmation of chlamydial infection. Sex Transm Infect 2002;78:225-6. http://dx.doi.org/10.1136/sti.78.3.225-a
191. Batteiger BE, Xu F, Johnson RE, Rekart ML. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J Infect Dis 2010;202: S178-89. http://dx.doi.org/10.1086/652400
192. LaMontagne DS, Baster K, Emmett L, Nicholls T, Randall S, McLean L, et al. Incidence and reinfection rates of genital chlamydial infection among women aged 16-24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory Group. Sex Transm Infect 2007;83:292-303. http://dx.doi.org/10.1136/sti.2006.022053
193. Price M, Ades A, De Angelis D, Welton NJ, Mcleod J, Turner K, et al. Incidence of Chlamydia trachomatis infection in England: two methods of estimation. Epidemiol Infect 2014;142:562-67. http://dx.doi.org/10.1017/S0950268813001027
194. Geisler WM, Morrison SG, Bachmann LH. Absence of Lymphogranuloma venereum strains among rectal Chlamydia trachomatis outer membrane protein A genotypes infecting women and men who have sex with men in Birmingham, Alabama. Sex Transm Dis 2008;35:856-8. http://dx.doi.org/10.1097/OLQ.0b013e3181788313
195. Fenton KA, Korovessis C, Johnson AM, McCadden A, McManus S, Wellings K, et al. Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection. Lancet 2001;358:1851-4. http://dx.doi.org/10.1016/S0140-6736(01)06886-6
196. McCadden A, Fenton KA, McManus S, Mercer CH, Erens B, Carder C, et al. Chlamydia trachomatis testing in the second British national survey of sexual attitudes and lifestyles: respondent uptake and treatment outcomes. Sex Transm Dis 2005;32:387-94. http://dx.doi.org/10.1097/01.olq.0000162364.65643.08
197. Office for National Statistics (ONS). Population Estimates for Years 2000-2010. London: ONS; 2014. (www.ons.gov.uk/ons/datasets-and-tables/index.html.)
198. Health Protection Agency (HPA). STI Episodes seen in GUM Clinics: Annual Data Tables 2008. London: HPA; 2010. (www.hpa.org.uk/stiannualdatatables.)
199. Rees E. The treatment of pelvic inflammatory disease. Am J Obstet Gynecol 1980;138:1042-7.
200. Hook EW, Spitters C, Reichart CA, Neumann TM, Quinn TC. Use of cell-culture and a rapid diagnostic assay for Chlamydia trachomatis screening. JAMA 1994;272:867-70. http://dx.doi.org/10.1001/jama.1994.03520110047027
201. Price M, Ades A, De Angelis D, Welton NJ, Mcleod J, Soldan K, et al. Risk of Pelvic Inflammatory Disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model. Am J Epidemiol 2013;178:484-92. http://dx.doi.org/10.1093/aje/kws583
202. Bachmann LH, Richey CM, Waites K, Schwebke JR, Hook EW. Patterns of Chlamydia trachomatis testing and follow-up at a university hospital medical center. Sex Transm Dis 1999;26:496-9. http://dx.doi.org/10.1097/00007435-199910000-00002
203. Stamm WE, Guinan ME, Johnson C, Starcher T, Holmes KK, Mccormack WM. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med 1984;310:545-9. http://dx.doi.org/10.1056/NEJM198403013100901
204. Westergaard L, Philipsen T, Scheibel J. Significance of cervical Chlamydia trachomatis infection in post-abortal pelvic inflammatory disease. Obstet Gynecol 1982;60:322-5.
205. Michel C-EC, Sonnex C, Carne CA, White JA, Magbanua JP, Nadala JC Jr, et al. Chlamydia trachomatis load at matched anatomic sites: Implications for screening strategies. J Clin Microbiol 2007;45:1395-402. http://dx.doi.org/10.1128/JCM.00100-07
206. Geisler WM, Suchland RJ, Whittington WLH, Stamm WE. Quantitative culture of Chlamydia trachomatis: relationship of inclusion-forming units produced in culture to clinical manifestations and acute inflammation in urogenital disease. J Infect Dis 2001;184:1350-4. http://dx.doi.org/10.1086/323998
207. Wiggins R, Graf S, Low N, Horner PJ, Chlamydia Screening Studies (ClaSS) Screening Group. Real-time quantitative PCR to determine chlamydial load in men and women in a community setting. J Clin Microbiol 2009;47:1824-9. http://dx.doi.org/10.1128/JCM.00005-09
208. Herzog SA, Heijne JCM, Althaus CL, Low N. Describing the progression from Chlamydia trachomatis and Neisseria gonorrhoeae to pelvic inflammatory disease: systematic review of mathematical modeling studies. Sex Transm Dis 2012;39:628-37. http://dx.doi.org/10.1097/OLQ.0b013e31825159ff
209. Grimmett G, Stirzaker D. Probability and Random Processes. 2nd edn. Oxford: Oxford University Press; 1992.
210. Price MJ, Welton NJ, AE A. Parameterisation of treatment effects for meta-analysis in multi-state Markov models. Stat Med 2011;30:140-51. http://dx.doi.org/10.1002/sim.4059
211. Welton NJ, Ades AE. Estimation of Markov Chain transition probabilities and rates from fully and partially observed data: uncertainty propagation, evidence synthesis and model calibration. Med Decis Mak 2005;25:633-45. http://dx.doi.org/10.1177/0272989X05282637
212. Taylor H, Karlin S. An Introduction to Stochastic Modeling. 3rd edn. San Diego, CA: Academic Press; 2006.
213. Boeke AJP, van Bergen JEAM, Morre SA, van Everdingen JJE. The risk of pelvic inflammatory disease associated with urogenital infection with Chlamydia trachomatis: literature review. Ned Tijdschr Geneeskd 2005;149:878-84.
214. Andersen B, Ostergaard L, Puho E, Skriver MV, Schonheyder HC. Ectopic pregnancies and reproductive capacity after Chlamydia trachomatis positive and negative test results: a historical follow-up study. Sex Transm Dis 2005;32:377-81. http://dx.doi.org/10.1097/01.olq.0000154512.86651.07
215. Bakken IJ, Ghaderi S. Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: a historical follow-up study. BMC Infect Dis 2009;9:130. http://dx.doi.org/10.1186/1471-2334-9-130
216. Bakken IJ, Skjeldestad FE, Lydersen S, Nordbo SA. Births and ectopic pregnancies in a large cohort of women tested for Chlamydia trachomatis. Sex Transm Dis 2007;34:739-43. http://dx.doi.org/10.1097/01.olq.0000261326.65503.f6
217. Bakken IJ, Skjeldestad FE, Nordbo SA. Chlamydia trachomatis infections increase the risk for ectopic pregnancy: A population-based, nested case-control study. Sex Transm Dis 2007;34:166-9. http://dx.doi.org/10.1097/01.olq.0000230428.06837.f7
218. Brihmer C, Kallings I, Nord CE, Brundin J. Salpingitis: aspects of diagnosis and etiology - a 4-year study from a Swedish capital hospital. Eur J Obstet Gynecol Reprod Biol 1987;24:211-20. http://dx.doi.org/10.1016/0028-2243(87)90020-7
219. Aghaizu A, Adams EJ, Turner K, Kerry S, Hay P, Simms I, et al. What is the cost of pelvic inflammatory disease and how much could be prevented by screening for Chlamydia trachomatis? Cost analysis of the Prevention Of Pelvic Infection (POPI) trial. Sex Transm Infect 2011;87:312-17. http://dx.doi.org/10.1136/sti.2010.048694
220. Mardh PA. Tubal factor infertility, with special regard to chlamydial salpingitis. Curr Opin Infect Dis 2004;17:49-52. http://dx.doi.org/10.1097/00001432-200402000-00010
221. Oakeshott P, Kerry S, Atherton H, Aghaizu A, Hay S, Taylor Robinson D, et al. Community-based trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. Trials 2008;9:73. http://dx.doi.org/10.1186/1745-6215-9-73
222. Herzog S, Althaus C, Heijne J, Oakeshott P, Kerry S, Hay P, et al. Timing of progression from Chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical modelling study. BMC Infect Dis 2012;12:187. http://dx.doi.org/10.1186/1471-2334-12-187
223. Lazaro N. Sexually Transmitted Infections in Primary Care. 2006. RCGP/BASHH. London: BMJ Publishing Group; 2006. URL: www.rcgp.org and www.bashh.org/guidelines
224. Bevan CD, Johal BJ, Mumtaz G, Ridgway GL, Siddle NC. Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. Br J Obstet Gynaecol 1995;102:407-14. http://dx.doi.org/10.1111/j.1471-0528.1995.tb11294.x
225. Hoyme UB, Kentner A, Mylonas I. Laparoscopic diagnosis of chlamydial pelvic inflammatory disease and its impact on chlamydia screening programmes. Eur Obstet Gynaecol 2012;7:9-13.
226. Gottlieb SL, Xu F, Brunham RC. Screening and treating Chlamydia trachomatis genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials. Sex Transm Dis 2013;40:97-102. http://dx.doi.org/10.1097/olq.0b013e31827bd637
227. Wendel GD, Cox SM, Bawdon RE, Theriot SK, Heard MC, Nobles BJ. A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. Am J Obstet Gynecol 1991;164:1390-6. http://dx.doi.org/10.1016/0002-9378(91)91479-G
228. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929-37. http://dx.doi.org/10.1067/mob.2002.121625
229. Simms I, Eastick K, Mallinson H, Thomas K, Gokhale R, Hay P, et al. Associations between Mycoplasma genitalium, Chlamydia trachomatis and pelvic inflammatory disease. J Clin Pathol 2003;56:616-18. http://dx.doi.org/10.1136/jcp.56.8.616
230. Mascellino MT, Ciardi MR, Oliva A, Cecinato F, Hassemer MP, Borgese L. Chlamydia trachomatis detection in a population of asymptomatic and symptomatic women: correlation with the presence of serological markers for this infection. New Microbiol 2008;31:249-56.
231. Hughes G, Williams T, Simms I. Trends in Diagnoses of Genital Chlamydia and Pelvic Inflammatory Disease in Primary Care, 1990-2003: Analysis of Data in the General Practice Research Database. Health Protection Agency Annual Conference, University of Warwick, Warwick, 13-15 September 2004.
232. Westrom L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980;138:880-92.
233. Simms I, Warburton F, Westrom L. Diagnosis of pelvic inflammatory disease: time for a rethink. Sex Transm Infect 2003;79:491-4. http://dx.doi.org/10.1136/sti.79.6.491
234. Ross J, McCarthy G. UK National Guideline for the Management of Pelvic Inflammatory Disease. Macclesfield: BASHH; 2011.
235. Taylor-Robinson D, Jensen JS, Svenstrup HF, Stacey CM. Difficulties experienced in defining the microbial cause of pelvic inflammatory disease. Int J STD AIDS 2012;23:18-24. http://dx.doi.org/10.1258/ijsa.2011.011066
236. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS: a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37. http://dx.doi.org/10.1023/A:1008929526011
237. Bjartling C, Osser S, Persson K. Mycoplasma genitalium in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service. Am J Obstet Gynecol 2012;206:476.e1-8. http://dx.doi.org/10.1016/j.ajog.2012.02.036
238. Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. NVHS Vital Health Stat 2005;23:1-160.
239. Buchan H, Vessey M, Goldacre M, Fairweather J. Morbidity following pelvic inflammatory disease. Br J Obstet Gynaecol 1993;100:558-62. http://dx.doi.org/10.1111/j.1471-0528.1993.tb15308.x
240. Heinonen PK, Leinonen M. Fecundity and morbidity following acute pelvic inflammatory disease treated with doxycycline and metronidazole. Arch Gynecol Obstet 2003;268:284-8. http://dx.doi.org/10.1007/s00404-002-0376-6
241. Safrin S, Schachter J, Dahrouge D, Sweet RL. Long-term sequelae of acute pelvic inflammatory disease: a retrospective cohort study. Am J Obstet Gynecol 1992;166:1300-5. http://dx.doi.org/10.1016/S0002-9378(11)90626-7
242. Gerber B, Krause A. A study of second-look laparoscopy after acute salpingitis. Arch Gynecol Obstet 1996;258:193-200. http://dx.doi.org/10.1007/s004040050123
243. Bernsteine R, Kennedy WR, Waldron J. Acute pelvic inflammatory disease: a clinical follow-up. Int J Fertil 1987;32:229-32.
244. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000;356:1013-19. http://dx.doi.org/10.1016/S0140-6736(00)02699-4
245. Farley TMM, Rowe PJ, Meirik O, Rosenberg MJ, Chen JH. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-8. http://dx.doi.org/10.1016/0140-6736(92)91904-M
246. Bouyer J, Coste J, Shojaei T, Pouly JL, Fernandez H, Gerbaud L, et al. Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case-control, population-based study in France. Am J Epidemiol 2011;157:185-94. http://dx.doi.org/10.1093/aje/kwf190
247. Coste J, Laumon B, Bremond A, Collet P, Jobspira N. Sexually-transmitted diseases as major causes of ectopic pregnancy: results from a large case-control study in France. Fertil Steril 1994;62:289-95.
248. Ramsey SD, Sullivan SD. Weighing the economic evidence: guidelines for the critical assessment of cost-effectiveness analyses. J Am Board Fam Pract 1999;12:477-85. http://dx.doi.org/10.3122/jabfm.12.6.477
249. Dominici F. Combining contingency tables with missing dimensions. Biometrics 2000;56:546-53. http://dx.doi.org/10.1111/j.0006-341X.2000.00546.x
250. Dominici F, Parmigiani G, Reckhow KH, Wolpert RL. Combining information from related regressions. JABES 1997;2:313-32. http://dx.doi.org/10.2307/1400448
251. Teisala K, Heinonen PK, Aine R, Punnonen R, Paavonen J. Second laparoscopy after treatment of acute pelvic inflammatory disease. Obstet Gynecol 1987;69:343-6.
252. Wolner-Hanssen P, Westrom L. Second look laparoscopy after acute salpingitis. Obstet Gynecol 1983;61:702-4.
253. Pavletic AJ, Wolner-Hanssen P, Paavonen J, Hawes SE, Eschenbach DA. Infertility following pelvic inflammatory disease. Infect Dis Obstet Gynecol 1999;7:145-52. http://dx.doi.org/10.1155/S106474499900023X
254. Brihmer C, Kallings I, Nord CE, Brundin J. Second look laparoscopy; evaluation of 2 different antibiotic regimens after treatment of acute salpingitis. Eur J Obstet Gynecol Reprod Biol 1989;30:263-74. http://dx.doi.org/10.1016/0028-2243(89)90011-7
255. Maheshwari A, Hamilton M, Bhattacharya S. Effect of female age on the diagnostic categories of infertility. Hum Reprod 2008;23:538-42. http://dx.doi.org/10.1093/humrep/dem431
256. Kavanagh K, Wallace LA, Robertson C, Wilson P, Scoular A. Estimation of the risk of tubal factor infertility associated with genital chlamydial infection in women: a statistical modelling study. Int J Epidemiol 2013;42:493-503. http://dx.doi.org/10.1093/ije/dyt011
257. Hull MGR, Glazener CMA, Kelly NJ, Conway DI, Foster PA, Hinton RA, et al. Population study of causes, treatment, and outcome of infertility. BMJ 1985;291:1693-7. http://dx.doi.org/10.1136/bmj.291.6510.1693
258. Sweet RL. Pelvic inflammatory disease: current concepts of diagnosis and management. Curr Infect Dis Rep 2012;14:194-203. http://dx.doi.org/10.1007/s11908-012-0243-y
259. Ness RB, Soper DE, Richter HE, Randall H, Peipert JF, Nelson DB, et al. Chlamydia antibodies, chlamydia heat shock protein, and adverse sequelae after pelvic inflammatory disease: The PID Evaluation and Clinical Health (PEACH) Study. Sex Transm Dis 2008;35:129-35. http://dx.doi.org/10.1097/OLQ.0b013e3181557c25
260. Ross JDC, Radcliffe K, Ahmed-Jushuf I, Cowan F, Fitzgerald M, Wilson J, et al. National guideline for the management of pelvic infection and perihepatitis. Sex Transm Infect 1999;75:S54-6.
261. Cates W, Wasserheit JN. Genital Chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991;164:1771-81. http://dx.doi.org/10.1016/0002-9378(91)90559-A
262. Persson K. The role of serology, antibiotic susceptibility testing and serovar determination in genital chlamydial infections. Best Pract Res Clin Obstet Gynecol 2002;16:801-14. http://dx.doi. org/10.1053/beog.2002.0321
263. Kosseim M, Brunham RC. Fallopian tube obstruction as a sequela to Chlamydia trachomatis infection. European J Clin Microbiol 1986;5:584-90. http://dx.doi.org/10.1007/BF02017711
264. Johnson AM, Horner P. A new role for Chlamydia trachomatis serology? Sex Transm Infect 2008;84:79-80. http://dx.doi.org/10.1136/sti.2007.028472
265. Morré SA, Munk C, Persson K, Krüger-Kjaer S, van Dijk R, Meijer CJ, et al. Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies. J Clin Microbiol 2002;40:584-7. http://dx.doi.org/10.1128/JCM.40.2.584-587.2002
266. Hadgu A. Discrepant analysis: a biased and an unscientific method for estimating test sensitivity and specificity. J Clin Epidemiol 1999;52:1231-7. http://dx.doi.org/10.1016/S0895-4356(99)00101-8
267. Miller WC. Bias in discrepant analysis: when two wrongs don’t make a right. J Clin Epidemiol 1998;51:219-31. http://dx.doi.org/10.1016/S0895-4356(97)00264-3
268. Narvanen A, Puolakkainen M, Hao W, Kino K, Suni J. Detection of antibodies to Chlamydia trachomatis with peptide-based species-specific enzyme immunoassay. Infect Dis Obstet Gynecol 1997;5.
269. Wills GS, Horner PJ, Reynolds R, Johnson AM, Muir DA, Brown DW, et al. Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis Infection. Clin Vaccine Immunol 2009;16:835-43. http://dx.doi.org/10.1128/CVI.00021-09
270. Akande VA, Hunt LP, Cahill DJ, Caul EO, Ford WCL, Jenkins JM. Tubal damage in infertile women: prediction using chlamydia serology. Hum Reprod 2003;18:1841-7. http://dx.doi.org/10.1093/humrep/deg347
271. Conway D, Glazener CM, Caul EO, Hodgson J, Hull MG, Clarke SK, et al. Chlamydial serology in fertile and infertile women. Lancet 1984;1:191-3. http://dx.doi.org/10.1016/S0140-6736(84) 92113-5
272. Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis 2010;201: S114-25. http://dx.doi.org/10.1086/652397
273. Kihlstrom E, Lindgren R, Ryden G. Antibodies to Chlamydia trachomatis in women with infertility, pelvic inflammatory disease and ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol 1990;35:199-204. http://dx.doi.org/10.1016/0028-2243(90)90162-T
274. Land JA, Gijsen AP, Kessels AGH, Slobbe MEP, Bruggeman CA. Performance of five serological chlamydia antibody tests in subfertile women. Hum Reprod 2003;18:2621-7. http://dx.doi.org/10.1093/humrep/deg479
275. Price MJ, Ades AE, Welton NJ, Macleod J, Turner K, Simms I, et al. How much tubal factor infertility is caused by chlamydia? Estimation based on serological evidence adjusted for sensitivity and specificity. J Sex Transm Dis 2012;39:608-13. http://dx.doi.org/10.1097/OLQ.0b013e3182572475
276. Broeze KA, Opmeer BC, Coppus SF, Van Geloven N, Ales MF, Anestad G, et al. Chlamydia antibody testing and diagnosing tubal pathology in subfertile women: an individual patient data meta-analysis. Hum Reprod Update 2011;17:301-10. http://dx.doi.org/10.1093/humupd/dmq060
277. Green DM, Swets JA. Signal Detection Theory and Psychophysics. New York, NY: Wiley; 1966.
278. Persson K, Osser S, Birkelund S, Christiansen G, Brade H. Antibodies to Chlamydia trachomatis heat shock proteins in women with tubal factor infertility are associated with prior infection by C. trachomatis but not by C. pneumoniae. Hum Reprod 1999;14:1969-73. http://dx.doi.org/10.1093/humrep/14.8.1969
279. Claeskens G, Hjort NL. Model Selection and Model Averaging. Cambridge: Cambridge University Press; 2011.
280. Horner P, Wills G, Pebody R. A Comparative Study of Chlamydia trachomatis PGP3 Antibody Elisa and Two C. trachomatis Specific MOMP Peptide Assays on Sera from Young People in the Community. In Stary A, Byrne G, Caldwell HD, editors. Twelfth International Symposium on Human Chlamydial Infections, San Francisco, CA, 2010. pp. 453-6.
281. Horner PJ, Wills GS, Reynolds R, Johnson AM, Muir DA, Winston A, et al. Effect of time since exposure to Chlamydia trachomatis on chlamydia antibody detection in women: a cross-sectional study. Sex Transm Infect 2013;89:398-403. http://dx.doi.org/10.1136/sextrans-2011-050386
282. Chavkin W. The rise in ectopic pregnancy: exploration of possible reasons. Int J Gynecol Obstet 1982;20:341-50. http://dx.doi.org/10.1016/0020-7292(82)90066-2
283. Westrom L. Effect of acute pelvic inflammatory disease on fertility. Am J Obstet Gynecol 1975;121:707-13. http://dx.doi.org/10.1097/00006254-197508000-00022
284. Turner K, Adams E, Grant A, Macleod J, Bell G, Clarke J, et al. Costs and cost effectiveness of different strategies for chlamydia screening and partner notification: an economic and mathematical modelling study. BMJ 2011;342:c7250. http://dx.doi.org/10.1136/bmj.c7250
285. Anestad G, Lunde O, Moen M, Dalaker K. Infertility and chlamydial infection. Fertil Steril 1987;48:787-90.
286. McLachlan GJ, Peel D. Finite Mixture Models. New York, NY: Wiley; 2000. http://dx.doi.org/10.1002/0471721182
287. Soper DE. Pelvic inflammatory disease. Obstet Gynecol 2010;116:1459-60. http://dx.doi.org/10.1097/AOG.0b013e3181ffb0de
288. Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N. Mathematical models in the evaluation of health programmes. Lancet 2011;378:515-25. http://dx.doi.org/10.1016/S0140-6736(10)61505-X
289. Presanis AM, De Angelis D, Goubar A, Gill ON, Ades AE. Bayesian evidence synthesis for a transmission dynamic model for HIV among men who have sex with men. Biostatistics 2011;12:666-81. http://dx.doi.org/10.1093/biostatistics/kxr006
290. Birrell P, Ketsetzis G, Gay N, Cooper BS, Presanis AM, Harris RJ, et al. Bayesian modeling to unmask and predict influenza A/H1N1pdm dynamics in London. Proc Nat Acad Sci U S A 2011;108:18238-43. http://dx.doi.org/10.1073/pnas.1103002108
291. De Angelis D, Presanis A, Birrell P, Tomba G, House T. Four key challenges in infectious disease modelling using data from multiple sources. Epidemics 2015;10:83-7. http://dx.doi.org/10.1016/j.epidem.2014.09.004
292. Van Valkengoed GM. Asymptomatic Chlamydia trachomatis Infections: Should We Screen? Doctoral Dissertation. Wageningen: Vrije Universiteit, Ponsen en Looijen BV; 2001.
293. Dunson D, Baird D, Colombo B. Increased infertility with age in men and women. Obstet Gynecol 2004;103:51-6. http://dx.doi.org/10.1097/01.AOG.0000100153.24061.45